Advances in insulin therapies, including the development of insulin analogues with a faster or prolonged time of action, novel or targeted approaches to administration, new glucose monitoring systems, and novel pens and devices for administration have all contributed to the improved treatment of T1D patients. This evidence concerns the gene INS and type 1 diabetes mellitus.